688710 Shanghai InnoStar Bio-tech

Watchlist

40.15
+0.84+2.14%

Market Closed Dec 20 15:00 CST

5.66BMarket Cap38.61P/E (TTM)

About Shanghai InnoStar Bio-tech Company

The company was founded in 2010. Adhering to the core values of “scientific leadership, quality first, honesty and dedication, unity and mutual trust”, seeking survival through quality, winning customers through reputation, promoting development through innovation, and creating efficiency through management, it has successively passed GLP certification by NMPA, AAALAC certification, GLP certification by the Dutch government of an OECD member country, GLP certification by the US FDA, and CAP certification by the American Society of Pathologists. It is one of the new drug safety evaluation agencies with a complete quality control system and complete service content in China. The company's shares were listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on September 3, 2024.

Company Profile

Short Name-A益诺思生物

Company NameShanghai InnoStar Bio-tech Co., Ltd.

Listing DateSep 3, 2024

Issue Price19.06

Shares Offered35.24M share(s)

FoundedMay 12, 2010

Chairmanshuyuan wei

Legal Representativeyan chang

General Manageryan chang

Secretaryyan li

Employees1075

ProvinceShang Hai Shi

Phone021-50801259

Office AddressRoom 106, No. 199 Guo Shoujing Road, China (Shanghai) Pilot Free Trade Zone

Zip Code201203

Registered AddressRoom 106, No. 199 Guo Shoujing Road, China (Shanghai) Pilot Free Trade Zone

Fax021-50801259

Emailbo@innostar.cn

Websitehttps://www.innostar.cn/

Business License91310000555907546T

BusinessThe issuer is a comprehensive research and development service (CRO) enterprise specializing in providing biomedical non-clinical research services. As one of the earliest domestic companies that also has NMPA GLP certification, OECD GLP certification, and US FDA GLP inspection, it is in line with international standards, has competitive international service capabilities within the industry, and provides a full range of new drug research services that meet domestic and international declaration standards for pharmaceutical companies and research institutions around the world. The company's services mainly cover the three major segments of biomedicine early pharmacogenicity evaluation, non-clinical research, and clinical testing and translational research. Among them, the non-clinical research section specifically includes non-clinical safety evaluation, non-clinical pharmacokinetic research, and non-clinical pharmacodynamics research.